4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl-
Modify Date: 2025-09-10 13:34:54
![4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- Structure](https://image.chemsrc.com/caspic/default.png)
4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- structure
|
Common Name | 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- | ||
|---|---|---|---|---|
| CAS Number | 2160546-07-4 | Molecular Weight | 377.27 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C17H18Cl2N6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl-IACS-13909 is a specific and potent allosteric inhibitor of SHP2 that suppresses the signaling of RTK/MAPK pathway and overcomes multiple mechanisms underlying osimertinib resistance. IACS-13909 potently impedes the proliferation of tumors with a broad spectrum of RTKs as the oncogenic driver. Importantly, in NSCLC models with acquired resistance to osimertinib, IACS-13909 administered as a single agent or in combination with osimertinib potently reduces tumor cell proliferation in vitro and in vivo. Together, our findings provide preclinical evidence for using a SHP2 inhibitor as a therapeutic strategy in acquired EGFR inhibitor-resistant NSCLC. |
| Name | IACS-13909 |
|---|---|
| Synonym | More Synonyms |
| Molecular Formula | C17H18Cl2N6 |
|---|---|
| Molecular Weight | 377.27 |
| Storage condition | -20°C |
| 4-Piperidinamine, 1-[3-(2,3-dichlorophenyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl]-4-methyl- |